- Oxford Biomedica expected to start trading on London's Alternative Investment Market on December Friday 13, after the Marketletter went to press, following delays caused by two underwriters who withdrew from the offer. Instead of the L8 million ($13.2 milllion) expected from the placing and open offer for 10% of the company, only L5 million was raised after the underwriters pulled out (Marketletters passim). The company is "reserving its legal postion" on the matter, reports the Financial Times.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze